Navigation Links
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Date:9/4/2007

et lesion revacularization or TLR).

According to this comprehensive analysis of all head-to-head clinical studies between the CYPHER(R) Stent and the Taxus Stent, a blood clot (stent thrombosis) is 34 percent less likely to form in patients implanted with the CYPHER(R) Stent than in patients who receive the Taxus Stent -- a statistically significant difference [hazard ratio (HR) 0.66, 95 percent confidence interval (CI) 0.46 to 0.94, p=0.02]. In addition, the CYPHER(R) Stent significantly lowered the risk of reintervention by 26 percent versus the Taxus Stent (HR 0.74, CI 0.63 to 0.87, p<0.001).

While the overall risk of death was not significantly different between the two drug-eluting stents (HR 0.92, CI 0.74 to 1.13, p=0.43), the authors of the meta-analysis identified a trend toward a lower risk of heart attack with the CYPHER(R) Stent versus the Taxus Stent (HR 0.84, CI 0.69 to 1.03, p=0.10), especially after the first year of follow-up.

Events occurring after the first year of stent placement have fueled the discussion surrounding the safety of drug-eluting stents. When only patient- level data were used, the authors were able to assess the occurrence of events after the first year of follow-up. In this analysis, there was a significant 70 percent reduction in blood clots (p=0.004) and a 55 percent reduction in repeat heart attacks (p=0.006) in patients who received the CYPHER(R) Stent compared to patients implanted with a Taxus Stent.

"This meta-analysis substantially enriches the large body of evidence that interventional cardiologists have at their disposal to make the right choice for their patients," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I, Chief Medical Officer, Cordis Corporation. "Drug-eluting stents, like the CYPHER(R) Stent, continue to provide significant benefits for patients with coronary artery disease."

For this analysis of randomized controlled trials, the gold standard of clinical evidence in medicine, i
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... (NYSE: HRC ) invites you to listen to ... Conference in New York City on February 15, 2012, at ... to the live discussion via the internet link at  http://ir.hill-rom.com/events.cfm ... recorded replay of the discussion will be available one hour ...
... growing stronger and stronger for one of the most ... on February 21-22, 2012 at the Renaissance Zurich Hotel ... 150 top pharmaceutical executives already attending, people are already ... among the industry,s influential decision makers," says conference organizer ...
Cached Medicine Technology:World's Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event 2
(Date:9/21/2014)... CareSpan USA, Inc. announced today at the ... services agreement with Avera eCARE, a leading healthcare system ... Clinic in multiple states where Avera eCARE is licensed. ... joint services in remote and rural parts of North ... licensed. The two companies’ strategy is to focus on ...
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... was originally launched in 1997, and is used ... children and adults. Its active ingredient, budesonide, is ... the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the ... older than six years of age, Pulmicort Respules ...
(Date:9/21/2014)... an allergy to peanuts than raw peanuts, suggests an ... that specific chemical changes caused by the high temperatures ... body,s immune system, ,priming, the body to set off ... any peanuts. , The results might explain the difference ... the Western world compared to populations in East Asia, ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... "I want to help people who ... haven’t the money for chiropractors," said an inventor from ... a product for myself." , The Stretch is a ... thigh muscles and align the spine properly. It improves ... of pinched nerves. Compact and easy to use, it's ...
Breaking Medicine News(10 mins):Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Dry roasting could help trigger peanut allergy 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3
... Oral Suspension Also Approved--, WILMINGTON, Del., Feb. 28 ... and Drug Administration (FDA) has,approved the use of NEXIUM(R) ... for the short-term treatment of gastroesophageal reflux,disease (GERD) for ... unmet,need for pediatric patients., NEXIUM received approval in ...
... Hospital has entered,into an agreement with VISICU, Inc., ... and remote monitoring tools, eICU,technology enables off-site critical ... around the clock. The voice, video and data,technology ... rates and shorten hospital length of stay., ...
... Education, Body Mass Index training events for, physicians and ... ... adults, INDIANAPOLIS, Feb. 28 With obesity at the forefront ... the Indiana Department of Health today announced that they will be,hosting ...
... (NEWARK, N.J., Feb. 28, 2008) New Jersey State ... Administration Research Education) Award for Excellence in Research to ... Flynn, assistant professor at the College of Nursing at ... honored with three other C.A.R.E. award recipients during the ...
... technologies and ... medical advancements, AUSTIN, Texas, Feb. ... officially opened the expansion of its,heart hospital today with the introduction ... as the number one overall,cardiac program in the State of Texas ...
... CHICAGO, Feb. 28 The Female Health Company,(Amex: ... John Snow, Inc., which,implements the USAID | DELIVER PROJECT, ... the United States Agency for International,Development (USAID) programs., ... international donors,of contraceptives and condoms. The Agency developed an ...
Cached Medicine News:Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 2Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 3Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 4Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 5Health News:The Christ Hospital and VISICU Sign Agreement to Implement eICU(R) Program 2Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 2Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 2Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 4Health News:The Female Health Company Receives USAID DELIVER PROJECT Order for 6.1 Million Units 2
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic Economical Single use. Non-Sterile....
Medicine Products: